{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:16:22Z","timestamp":1788365782174,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23OC0086127"],"award-info":[{"award-number":["NNF23OC0086127"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:39:36Z","timestamp":1787312376000},"page":"5036-5038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modified siRNA downregulates an upstream immune adaptor to modify ocular diseases"],"prefix":"10.1016","volume":"34","author":[{"given":"Adriana","family":"Colmenares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-8285","authenticated-orcid":false,"given":"Chenguang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.010_bib1","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1016\/j.ymthe.2026.06.036","article-title":"Cell-penetrating asymmetric siRNA targeting MyD88 suppresses inflammasome-driven ocular degeneration and angiogenesis","volume":"34","author":"Kim","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.010_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.08.010_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ymthe.2026.08.010_bib4","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.2147\/IJN.S532074","article-title":"Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases","volume":"20","author":"Lin","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2026.08.010_bib5","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF pathway in cancer and disease: responses, resistance, and the path forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2026.08.010_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/ijcb\/6663816","article-title":"Important Aspects of siRNA Design for Optimal Efficacy In Vitro and In Vivo","volume":"2025","author":"Bhakta-Yadav","year":"2025","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.08.010_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.010_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/978-1-0716-1298-9_23","article-title":"siRNA Therapeutics in Ocular Diseases","volume":"2282","author":"Moreno-Monta\u00f1\u00e9s","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.010_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202504723","article-title":"Targeted Delivery of Avacopan via Sortase A-Modified Extracellular Vesicles Attenuates Endotoxin-Induced Retinal Inflammation","volume":"15","author":"Meng","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ymthe.2026.08.010_bib10","article-title":"In vivo efficacy of NRL knockdown with cell-penetrating siRNA in retinal degeneration","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600691X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600691X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:21:08Z","timestamp":1788362468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600691X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S152500162600691X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.010","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified siRNA downregulates an upstream immune adaptor to modify ocular diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.036","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}